Cargando…

Immune Response to Viruses: Antibody-Mediated Immunity

The notion about immunity to disease arose from the observation that those who recovered from an apparently contagious disease became resistant to a subsequent similar sickness. Much later it was shown that immunity is transferable by serum. The active serum components were identified to be immunogl...

Descripción completa

Detalles Bibliográficos
Autor principal: Neurath, A.R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149652/
http://dx.doi.org/10.1016/B978-012374410-4.00591-4
_version_ 1783520852710522880
author Neurath, A.R.
author_facet Neurath, A.R.
author_sort Neurath, A.R.
collection PubMed
description The notion about immunity to disease arose from the observation that those who recovered from an apparently contagious disease became resistant to a subsequent similar sickness. Much later it was shown that immunity is transferable by serum. The active serum components were identified to be immunoglobulins (Ig's), called antibodies. The enormous diversity of antibodies specific for distinct viruses, pathogens, and many other antigens is explained by clonal selection, whereby specific B-lymphocyte receptors recognize a particular antigen. The selected B-cells are triggered to undergo replication. A process of further cell differentiation and maturation ensues, leading to secretion of antibodies with high binding affinity toward the triggering antigen. Genes coding for the variable regions (involved in antigen binding) of Ig's are inherited as sets of gene fragments joined to form a complete gene in individual B-cells. This process and further hypermutations ensure the synthesis of diverse high affinity antibodies. The antibodies consist of pairs of light (L) and heavy (H) polypeptide chains. Variations in the constant portion of H-chains lead to production of Ig isotypes (IgM, IgA, IgD, IgE, and IgG (further subdivided into IgG1, IgG2, IgG3 and IgG4)), each having distinct effector functions. Host exposure to viruses leads to the production of antibodies with more than one specificity. Only some of these antibodies, recognizing so-called virus neutralization epitopes, diminish or eliminate virus infectivity. Other virus-specific antibodies play auxiliary roles or are ineffective. Sometimes antibodies cause enhancement of viral diseases or play a role in evasion of the immune system. Many antiviral immunoglobulins are being used for short-term pre-exposure prophylaxis or therapy. Long-term protective effects can be accomplished only by antibodies elicited by successful vaccination relying on the phenomenon of immunological memory. T-lymphocytes play a major role in initiating and maintaining immunity against subsequent virus exposure. Antibodies are one of the essential features of antigen triggered adaptive immunity. Initial early defense against viruses is provided by components of innate immunity which evolutionarily precedes adaptive immunity, and remains an essential part of defense against pathogens in humans.
format Online
Article
Text
id pubmed-7149652
institution National Center for Biotechnology Information
language English
publishDate 2008
record_format MEDLINE/PubMed
spelling pubmed-71496522020-04-13 Immune Response to Viruses: Antibody-Mediated Immunity Neurath, A.R. Encyclopedia of Virology Article The notion about immunity to disease arose from the observation that those who recovered from an apparently contagious disease became resistant to a subsequent similar sickness. Much later it was shown that immunity is transferable by serum. The active serum components were identified to be immunoglobulins (Ig's), called antibodies. The enormous diversity of antibodies specific for distinct viruses, pathogens, and many other antigens is explained by clonal selection, whereby specific B-lymphocyte receptors recognize a particular antigen. The selected B-cells are triggered to undergo replication. A process of further cell differentiation and maturation ensues, leading to secretion of antibodies with high binding affinity toward the triggering antigen. Genes coding for the variable regions (involved in antigen binding) of Ig's are inherited as sets of gene fragments joined to form a complete gene in individual B-cells. This process and further hypermutations ensure the synthesis of diverse high affinity antibodies. The antibodies consist of pairs of light (L) and heavy (H) polypeptide chains. Variations in the constant portion of H-chains lead to production of Ig isotypes (IgM, IgA, IgD, IgE, and IgG (further subdivided into IgG1, IgG2, IgG3 and IgG4)), each having distinct effector functions. Host exposure to viruses leads to the production of antibodies with more than one specificity. Only some of these antibodies, recognizing so-called virus neutralization epitopes, diminish or eliminate virus infectivity. Other virus-specific antibodies play auxiliary roles or are ineffective. Sometimes antibodies cause enhancement of viral diseases or play a role in evasion of the immune system. Many antiviral immunoglobulins are being used for short-term pre-exposure prophylaxis or therapy. Long-term protective effects can be accomplished only by antibodies elicited by successful vaccination relying on the phenomenon of immunological memory. T-lymphocytes play a major role in initiating and maintaining immunity against subsequent virus exposure. Antibodies are one of the essential features of antigen triggered adaptive immunity. Initial early defense against viruses is provided by components of innate immunity which evolutionarily precedes adaptive immunity, and remains an essential part of defense against pathogens in humans. 2008 2008-07-30 /pmc/articles/PMC7149652/ http://dx.doi.org/10.1016/B978-012374410-4.00591-4 Text en Copyright © 2008 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Neurath, A.R.
Immune Response to Viruses: Antibody-Mediated Immunity
title Immune Response to Viruses: Antibody-Mediated Immunity
title_full Immune Response to Viruses: Antibody-Mediated Immunity
title_fullStr Immune Response to Viruses: Antibody-Mediated Immunity
title_full_unstemmed Immune Response to Viruses: Antibody-Mediated Immunity
title_short Immune Response to Viruses: Antibody-Mediated Immunity
title_sort immune response to viruses: antibody-mediated immunity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149652/
http://dx.doi.org/10.1016/B978-012374410-4.00591-4
work_keys_str_mv AT neurathar immuneresponsetovirusesantibodymediatedimmunity